Cargando…

Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence

AIM: Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients. METHODS: Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies. RESULTS: Disease-free proportion decreased in stage III vs stage I p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jovanoski, Nick, Bowes, Kathleen, Brown, Audrey, Belleli, Rossella, Di Maio, Danilo, Chadda, Shkun, Abogunrin, Seye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485735/ https://www.ncbi.nlm.nih.gov/pubmed/37693293 http://dx.doi.org/10.2217/lmt-2023-0003

Ejemplares similares

Treatment patterns and survival of patients with locoregional recurrence in early-stage NSCLC: a literature review of real-world evidence
por: Bowes, Kathleen, et al.
Publicado: (2022)

Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC)
por: Jovanoski, Nick, et al.
Publicado: (2023)

Health State Utility Values in Early-Stage Non-small Cell Lung Cancer: A Systematic Literature Review
por: Jovanoski, Nick, et al.
Publicado: (2023)

A Network Meta-Analysis of Cancer Immunotherapies Versus Chemotherapy for First-Line Treatment of Patients With Non-Small Cell Lung Cancer and High Programmed Death-Ligand 1 Expression
por: Herbst, Roy, et al.
Publicado: (2021)

Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments
por: Winstone, Julie, et al.
Publicado: (2015)

Is there an Exposure–Response Relationship for Nivolumab in Real-World NSCLC Patients?
por: Bellesoeur, Audrey, et al.
Publicado: (2019)

Early introduction of a semi-elemental formula may be cost saving compared to a polymeric formula among critically ill patients requiring enteral nutrition: a cohort cost–consequence model
por: Curry, Alistair S, et al.
Publicado: (2018)

Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data
por: Wang, Xuechen, et al.
Publicado: (2022)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario
por: Flores Vega, Yoanna I., et al.
Publicado: (2023)

Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review
por: Martin, Alison, et al.
Publicado: (2014)

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World
por: Pasello, Giulia, et al.
Publicado: (2022)

Real Women, Real Leaders: Surviving and Succeeding in the Business World
por: Hurley, Kathleen
Publicado: (2015)

Osimertinib in NSCLC: Real-World Data From New Zealand
por: So, Yeojeong Jane, et al.
Publicado: (2020)

Real-world insights into patients with advanced NSCLC and MET alterations
por: Bittoni, Marisa, et al.
Publicado: (2021)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ariyasu, Ryo, et al.
Publicado: (2023)

Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC—Real World Efficacy
por: Mouritzen, Mette T., et al.
Publicado: (2021)

Systematic literature review and assessment of patient-reported outcome instruments in sickle cell disease
por: Sarri, Grammati, et al.
Publicado: (2018)

Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study
por: Thronicke, Anja, et al.
Publicado: (2020)

Clinical predictors of survival in real world practice in stage IV melanoma
por: Hu, Hsien‐Pang, et al.
Publicado: (2022)

AbobotulinumtoxinA in the management of cervical dystonia in the United Kingdom: a budget impact analysis
por: Abogunrin, Seye, et al.
Publicado: (2015)

Prevalence of human papillomavirus in head and neck cancers in European populations: a meta-analysis
por: Abogunrin, Seye, et al.
Publicado: (2014)

Cost-effectiveness analysis of abobotulinumtoxinA for the treatment of cervical dystonia in the United Kingdom
por: Muthukumar, Madhusubramanian, et al.
Publicado: (2017)

Durvalumab after Chemoradiotherapy for PD-L1 Expressing Inoperable Stage III NSCLC Leads to Significant Improvement of Local-Regional Control and Overall Survival in the Real-World Setting
por: Taugner, Julian, et al.
Publicado: (2021)

Comprehensive analysis of MET mutations in NSCLC patients in a real-world setting
por: Ai, Xinghao, et al.
Publicado: (2022)

Patient-Reported Outcomes and Economic Burden of Adults with Sickle Cell Disease in the United States: A Systematic Review
por: Lee, Soyon, et al.
Publicado: (2020)

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2021)

A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting
por: Terrenato, Irene, et al.
Publicado: (2022)

Impact of marital status on survival in patients with stage 1A NSCLC
por: Huang, Liu, et al.
Publicado: (2022)

Real‐world treatment and prognostic factors for survival in ALK+ non‐small cell lung cancer (NSCLC) patients with brain metastases in China
por: Li, Na, et al.
Publicado: (2022)

Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom
por: Abogunrin, Seye, et al.
Publicado: (2015)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data
por: Moskovitz, Mor, et al.
Publicado: (2022)

Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting
por: Li, Jia, et al.
Publicado: (2022)

Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience
por: Cronin, Christopher, et al.
Publicado: (2023)

Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2023)

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients
por: Thronicke, Anja, et al.
Publicado: (2020)

Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC
por: Wei, Yongyue, et al.
Publicado: (2018)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u5jpor2e0suvh2bjrnigtt44nt